Professor of Medicine
Professor of Biostatistics and Bioinformatics
Member in the Duke Clinical Research Institute
Member of Duke Molecular Physiology Institute
Dr. Shah’s translational research laboratory focuses on understanding metabolic and genetic pathways of cardiometabolic diseases. Her lab integrates genomic, metabolomic and proteomic techniques for identification of novel mechanisms of disease and biomarkers. Her multi-disciplinary, collaborative molecular epidemiology lab has quantitative and molecular components leverages large biorepositories to perform discovery studies using omics technologies, with subsequent functional validation for mechanistic insight. Her laboratory studies diverse cardiometabolic diseases with a focus on obesity, heart failure and atherosclerosis. Dr. Shah also works closely with the Duke Clinical Research Institute for biomarker discovery efforts in large cardiovascular clinical trials and is Director of the Duke Kannapolis research program which includes a large, diverse community-based cohort in North Carolina and the Project Baseline study. Dr. Shah also works closely as a volunteer for the American Heart Association, serving as Chair of the AHA’s Research Committee, former Chair of the Genomic and Precision Medicine Council, and an Associate Editor for Circulation. Our work is funded by the National Institutes of Health and the American Heart Association.
MHS, Medical Genomics, Duke University, Durham, NC
MD, University of Washington, Seattle, WA
MHS., Johns Hopkins School of Public Health, Baltimore, MD
My research laboratory studies the molecular epidemiology of cardiometabolic diseases, utilizing metabolomic, genomic, proteomic and bioinformatics methods in a "systems biology" approach to identify novel biomarkers and mechanisms of disease pathogenesis. We lead several large cardiometabolic cohort studies including the Duke Kannapolis study, Project Baseline, PROMISE, EPGEN, CATHGEN and others, and we lead biomarker discovery efforts in large clinical trials through collaborations with the Duke Clinical Research Institute. The laboratory encompasses a significant computational component with statistician geneticists and biostatisticians, a clinical research component, as well as a wet lab component for genomic and proteomic analyses. We also work closely with the metabolomics core within the DMPI for metabolic studies. While we collaborate broadly across many diseases, our focus is on obesity, heart failure and atherosclerosis. Another facet of our laboratory is the study of monogenic disorders including studying patients with hereditary cardiovascular disorders in the Duke Adult Cardiovascular Genetics Clinic. Our work has resulted in the identification of novel CAD genes; metabolic biomarkers that predict incident CVD events; novel pathways of CVD event pathogenesis; and a greater understanding of the burden of monogenic cardiovascular disorders.
Metabolic Pathways and Cardiac Metabolism in Obesity and Heart Failure
The Shah lab has a research program in identifying metabolic pathways and related biomarkers of obesity and heart failure. We have identified novel metabolic pathways and relevant clinical markers of cardiometabolic disease risk including branched chain amino acids (BCAA) in obesity, insulin resistance, diabetes and response to weight loss interventions; and impaired mitochondrial fatty acid oxidation in heart failure. Cohorts we have collaboratively studied include the POMMS pediatric obesity cohort; surgical weight loss interventions; the Weight Loss Maintenance clinical trial; the STRRIDe clinical trial of exercise in metabolic syndrome; the EXCITE clinical trial of left ventricular diastolic dysfunction and exercise; the HF-Action clinical trial; the EXSCEL and TECOS clinical trials; and studies within the NHLBI Heart Failure Network.
Proteomics and Integrated Omics in Atherosclerosis and Cardiometabolic Diseases
The Shah lab has a research program in using integrated omics in a systemic biology approach to identify novel pathways in atherosclerosis and cardiometabolic diseases. For example, we are studying integrated metabolic, proteomic and genomic pathways for identify of novel molecular mediators and related biomarkers for high risk coronary plaque in the PROMISE clinical trial.
Monogenic Cardiovascular Diseases
The Shah lab has a research program in understanding the prevalence, penetrance and missed opportunity of monogenic cardiovascular diseases. In addition, we have begun a research and clinical program in clonal hematopoiesis of indeterminate potential (CHIP).
Duke Kannapolis Research
Dr. Shah is Director of the Duke Kannapolis Research site which includes an ongoing longitudinal, diverse population-based cohort in North Carolina, the MURDOCK study, with clinical data, biospecimens and a highly engaged cohort. We would be happy to discuss collaborative studies in this unique cohort.